Sickle Cell Disease (SCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Sickle cell disease (SCD) results from homozygous and compound heterozygote inheritance of a mutation in the β-globin gene. This genetic anomaly leads to the formation of dense and rigid red blood cells (RBCs), particularly those containing HbS or HbS in combination with other abnormal β alleles. When exposed to a deoxygenated environment, these RBCs undergo polymerization, becoming rigid and prone to haemolysis. The increased density of these cells can impact blood flow and compromise endothelial vessel wall integrity, causing vaso-occlusion, tissue ischemia, infarction, and further haemolysis. The consequences of haemolysis set off a complex cascade of events, including nitric oxide consumption, intricately linked to nitric oxide dysregulation and endothelial dysfunction. These underlying factors contribute to complications such as leg ulceration, stroke, pulmonary hypertension, and priapism. In a significant development in 2023, the U.S. Food and Drug Administration (FDA) approved two groundbreaking treatments, Casgevy and Lyfgenia, marking the introduction of the first cell-based gene therapies for treating SCD in patients 12 years and older. Notably, Casgevy represents a milestone as the first FDA-approved treatment utilizing a novel genome editing technology. This advancement opens new avenues for managing SCD and offers hope for improved outcomes in affected individuals.
• The incidence of sickle cell disease (SCD) ranges between 27 and 35 cases per 100,000 people in the USA.

Thelansis’s “Sickle Cell Disease (SCD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sickle Cell Disease (SCD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Sickle Cell Disease (SCD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Sickle Cell Disease (SCD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Sickle Cell Disease (SCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Sickle Cell Disease (SCD), Sickle Cell Disease (SCD) market outlook, Sickle Cell Disease (SCD) competitive landscape, Sickle Cell Disease (SCD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)